JP2018500375A - 続発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 - Google Patents

続発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 Download PDF

Info

Publication number
JP2018500375A
JP2018500375A JP2017534946A JP2017534946A JP2018500375A JP 2018500375 A JP2018500375 A JP 2018500375A JP 2017534946 A JP2017534946 A JP 2017534946A JP 2017534946 A JP2017534946 A JP 2017534946A JP 2018500375 A JP2018500375 A JP 2018500375A
Authority
JP
Japan
Prior art keywords
secondary hyperparathyroidism
subject
calcium
patients
effective amount
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2017534946A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018500375A5 (enExample
Inventor
ヘクター エフ． デルーカ
ヘクター エフ． デルーカ
ローリー エイ． プラム
ローリー エイ． プラム
マーガレット クラーゲット−デーム
マーガレット クラーゲット−デーム
Original Assignee
ウイスコンシン アラムニ リサーチ ファンデーション
ウイスコンシン アラムニ リサーチ ファンデーション
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ウイスコンシン アラムニ リサーチ ファンデーション, ウイスコンシン アラムニ リサーチ ファンデーション filed Critical ウイスコンシン アラムニ リサーチ ファンデーション
Publication of JP2018500375A publication Critical patent/JP2018500375A/ja
Publication of JP2018500375A5 publication Critical patent/JP2018500375A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/137—Arylalkylamines, e.g. amphetamine, epinephrine, salbutamol, ephedrine or methadone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A61P5/20—Drugs for disorders of the endocrine system of the parathyroid hormones for decreasing, blocking or antagonising the activity of PTH

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Emergency Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2017534946A 2014-12-30 2015-12-11 続発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用 Pending JP2018500375A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201462098112P 2014-12-30 2014-12-30
US62/098,112 2014-12-30
US14/710,746 2015-05-13
US14/710,746 US9539264B2 (en) 2014-12-30 2015-05-13 Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
PCT/US2015/065175 WO2016109156A1 (en) 2014-12-30 2015-12-11 Use of 2-methylene-19-nor-(20s)-1a,25-dihydroxyvitamin d3 to treat secondary hyperparathyroidism

Publications (2)

Publication Number Publication Date
JP2018500375A true JP2018500375A (ja) 2018-01-11
JP2018500375A5 JP2018500375A5 (enExample) 2018-09-13

Family

ID=56162990

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2017534946A Pending JP2018500375A (ja) 2014-12-30 2015-12-11 続発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用

Country Status (6)

Country Link
US (2) US9539264B2 (enExample)
EP (1) EP3240549A4 (enExample)
JP (1) JP2018500375A (enExample)
AU (1) AU2015374468A1 (enExample)
CA (1) CA2969334A1 (enExample)
WO (1) WO2016109156A1 (enExample)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
US10105375B2 (en) 2016-08-30 2018-10-23 Wisconsin Alumni Research Foundation Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531327A (ja) * 2006-03-23 2009-09-03 アムゲン インコーポレイティッド シナカルセットの多形体の製造および使用のための方法および組成物
WO2013071262A1 (en) * 2011-11-10 2013-05-16 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
WO2014003849A1 (en) * 2012-06-29 2014-01-03 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
CA2404335C (en) 2000-03-27 2009-01-06 Wisconsin Alumni Research Foundation Vitamin d compounds used to stabilize kidney transplants
MXPA03000406A (es) 2000-07-14 2003-06-06 Wisconsin Alumni Res Found Uso de 2-metilen-19-nor-20(s)-1 alfa,25-dihidroxivitamina d3 para incrementar la resistencia de los huesos.
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
EP1853274B1 (en) 2005-02-11 2013-01-23 Wisconsin Alumni Research Foundation 2-methylene-19-nor- (20s-24s) - 1alpha, 25-dihydroxyvitamine-d2
US20060276534A1 (en) 2005-03-17 2006-12-07 Amgen Inc. Methods of decreasing calcification
DK3225243T3 (da) * 2007-04-25 2025-09-29 Opko Renal Llc Metode til sikker og effektiv behandling og forebyggelse af sekundær hyperparatyreoidisme ved kronisk nyresygdom
CA2764577C (en) 2009-08-03 2017-12-19 Wisconsin Alumni Research Foundation Method of preventing renal disease and treating symptoms thereof
CA2794006C (en) 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
US20130295083A1 (en) 2012-05-02 2013-11-07 Wisconsin Alumni Research Foundation 2a-Methyl-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2AMD) or 2 methylene-19-nor-(20S)-1a,25-dihydroxyvitamin D3 (2MD) Support Survival and Function of Transplanted Islet Cells In Type 1 Diabetes
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2009531327A (ja) * 2006-03-23 2009-09-03 アムゲン インコーポレイティッド シナカルセットの多形体の製造および使用のための方法および組成物
WO2013071262A1 (en) * 2011-11-10 2013-05-16 Kai Pharmaceuticals, Inc. Calcimimetics and methods for their use
WO2014003849A1 (en) * 2012-06-29 2014-01-03 Wisconsin Alumni Research Foundation USE OF 2-METHYLENE-19-NOR-(20S)-1α,25-DIHYDROXYVITAMIN D3 TO TREAT SECONDARY HYPERPARATHYROIDISM

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
"A new role for vitamin D receptor activation in chronic kidney disease", AMERICAN JOURNAL OF PHYSIOLOGY, vol. 297 (6), JPN6019014010, 2009, pages 1502 - 1509, ISSN: 0004153195 *
"Cinacalcet hydrochlorideと経口合成ビタミンD3製剤の併用療法を中心としたCKD‐MBD治療の検討—レグパラは", KITAKANTO MEDICAL JOURNAL, vol. 60 (1), JPN6019014011, 2010, pages 77, ISSN: 0004153196 *

Also Published As

Publication number Publication date
US9814736B2 (en) 2017-11-14
WO2016109156A1 (en) 2016-07-07
CA2969334A1 (en) 2016-07-07
US20170042913A1 (en) 2017-02-16
AU2015374468A1 (en) 2017-06-22
US20160184328A1 (en) 2016-06-30
EP3240549A4 (en) 2018-08-29
US9539264B2 (en) 2017-01-10
EP3240549A1 (en) 2017-11-08

Similar Documents

Publication Publication Date Title
US10046000B2 (en) Use of 2-methylene-19-nor-(20S)-1α,25-Dihydroxyvitamin D3 to treat and prevent secondary hyperparathyroidism in a subject having renal failure
JP6095891B2 (ja) ２５−ヒドロキシビタミンｄ３を含む経口剤形、及び、その経口剤形を週１回ヒトに投与することを含む方法
JP3529790B2 (ja) 続発性上皮小体機能亢進症の治療のための薬剤の製造におけるビタミンｄ▲下２▼又はビタミンｄ▲下４▼誘導体の用途
EP2490695A1 (en) Method of preventing type 1 diabetes
US9814736B2 (en) Use of 2-methylene-19-nor-(20S)-1α,25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
Sorbera et al. Cinacalcet hydrochloride
JPH11502862A (ja) 腎機能障害患者における燐酸塩過剰血症予防のための１９−ノル−ビタミンｄ化合物の使用
US10105375B2 (en) Combination of low dose 2-methylene-19-nor-(20S)1α, 25-dihydroxyvitamin D3 and calcimimetics to treat secondary hyperparathyroidism
WO2012106947A1 (zh) 含维生素d和二甲双胍的药物组合物
JP2018500373A (ja) 原発性副甲状腺機能亢進症を処置するための２−メチレン−１９−ノル−（２０Ｓ）−１α，２５−ジヒドロキシビタミンＤ３の使用
CN101018586B (zh) 含锶和维生素d的组合物及其用途
JPS6045517A (ja) １α−ヒドロキシビタミンＤ↓３類を含有する抗筋ジストロフイ−症剤

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20171006

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180802

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20180802

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20190411

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20190418

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20191114